Mesenchymal migration as a therapeutic target in glioblastoma

Journal of Oncology

Volumn , Issue , 2010, Pages

  O'Neill, Geraldine M ^a,b   Zhong, Jessie ^a   Paul, Andre ^a,b   Kellie, Stewart J ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ACTIN; CELL ADHESION MOLECULE; CILENGITIDE; DASATINIB; ERLOTINIB; INTEGRIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; CYTOLOGY; CYTOSKELETON; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MESENCHYME; MORTALITY; NONHUMAN; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TUMOR CELL;

EID: 77955378377     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/430142     Document Type: Review

References (239)

1. Nakada M., Nakada S., Demuth T., Tran N. L., Hoelzinger D. B., Berens M. E., Molecular targets of glioma invasion Cellular and Molecular Life Sciences 2007 64 4 458 478
2. Furnari F. B., Fenton T., Bachoo R. M., Mukasa A., Stommel J. M., Stegh A., Hahn W. C., Ligon K. L., Louis D. N., Brennan C., Chin L., DePinho R. A., Cavenee W. K., Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes and Development 2007 21 21 2683 2710
3. Hou L. C., Veeravagu A., Hsu A. R., Tse V. C., Recurrent glioblastoma multiforme: a review of natural history and management options Neurosurgical Focus 2006 20 4 E5
4. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma The New England Journal of Medicine 2005 352 10 987 996
5. Tracey E., Baker D., Chen W., Stavrou E., Bishop J., Cancer in New South Wales: Incidence, Mortality and Prevalence, 2005 2007 Sydney, Australia Cancer Institute NSW
6. Surawicz T. S., Davis F., Freels S., Laws E. R. Jr., Menck H. R., Brain tumor survival: results from the national cancer data base Journal of Neuro-Oncology 1998 40 2 151 160
7. Lee S. W., Fraass B. A., Marsh L. H., Herbort K., Gebarski S. S., Martel M. K., Radany E. H., Lichter A. S., Sandler H. M., Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study International Journal of Radiation Oncology Biology Physics 1999 43 1 79 88
8. van Nifterik K. A., Elkhuizen P. H. M., van Andel R. J., Stalpers L. J. A., Leenstra S., Lafleur M. V. M., Vandertop W. P., Slotman B. J., Hulsebos T. J. M., Sminia P., Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: recurrence or second primary tumor? Journal of Neurosurgery 2006 105 5 739 744
9. Bellail A. C., Hunter S. B., Brat D. J., Tan C., Van Meir E. G., Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion International Journal of Biochemistry and Cell Biology 2004 36 6 1046 1069
10. Giese A., Laube B., Zapf S., Mangold U., Westphal M., Glioma cell adhesion and migration on human brain sections Anticancer Research 1998 18 4A 2435 2447
11. Rao J. S., Molecular mechanisms of glioma invasiveness: the role of proteases Nature Reviews Cancer 2003 3 7 489 501
12. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W., Kleihues P., The 2007 WHO classification of tumours of the central nervous system Acta Neuropathologica 2007 114 2 97 109
13. Ohgaki H., Kleihues P., Genetic pathways to primary and secondary glioblastoma American Journal of Pathology 2007 170 5 1445 1453
14. Kleihues P., Ohgaki H., Primary and secondary glioblastomas: from concept to clinical diagnosis Neuro-Oncology 1999 1 1 44 51
15. Frederick L., Wang X.-Y., Eley G., James C. D., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Research 2000 60 5 1383 1387
16. Nishikawa R., Ji X.-D., Harmon R. C., Lazar C. S., Gill G. N., Cavenee W. K., Huang H.-J. S., A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proceedings of the National Academy of Sciences of the United States of America 1994 91 16 7727 7731
17. Biernat W., Kleihues P., Yonekawa Y., Ohgaki H., Amplification and overexpression of MDM2 in primary (de novo) glioblastomas Journal of Neuropathology and Experimental Neurology 1997 56 2 180 185
18. Halatsch M.-E., Schmidt U., Unterberg A., Vougioukas V. I., Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status Anticancer Research 2006 26 6B 4191 4194
19. Schmidt E. E., Ichimura K., Reifenberger G., Collins V. P., CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas Cancer Research 1994 54 24 6321 6324
20. Wang S. I., Puc J., Li J., Bruce J. N., Cairns P., Sidransky D., Parsons R., Somatic mutations of PTEN in glioblastoma multiforme Cancer Research 1997 57 19 4183 4186
21. Wong A. J., Bigner S. H., Bigner D. D., Kinzler K. W., Hamilton S. R., Vogelstein B., Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification Proceedings of the National Academy of Sciences of the United States of America 1987 84 19 6899 6903
22. Sieg D. J., Hauck C. R., Ilic D., Klingbeil C. K., Schaefer E., Damsky C. H., Schlaepfer D. D., FAK integrates growth-factor and integrin signals to promote cell migration Nature Cell Biology 2000 2 5 249 256
23. Tamura M., Gu J., Matsumoto K., Aota S.-I., Parsons R., Yamada K. M., Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN Science 1998 280 5369 1614 1617
24. Tamura M., Gu J., Takino T., Yamada K. M., Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas Cancer Research 1999 59 2 442 449
25. Maher E. A., Furnari F. B., Bachoo R. M., Rowitch D. H., Louis D. N., Cavenee W. K., DePinho R. A., Malignant glioma: genetics and biology of a grave matter Genes and Development 2001 15 11 1311 1333
26. James C. D., Carlbom E., Dumanski J. P., Hansen M., Nordenskjold M., Collins V. P., Cavenee W. K., Clonal genomic alterations in glioma malignancy stages Cancer Research 1988 48 19 5546 5551
27. Louis D. N., The p53 gene and protein in human brain tumors Journal of Neuropathology and Experimental Neurology 1994 53 1 11 21
28. Watanabe K., Sato K., Biernat W., Tachibana O., Von Ammon K., Ogata N., Yonekawa Y., Kleihues P., Ohgaki H., Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies Clinical Cancer Research 1997 3 4 523 530
29. Tso C.-L., Freije W. A., Day A., Chen Z., Merriman B., Perlina A., Lee Y., Dia E. Q., Yoshimoto K., Mischel P. S., Liau L. M., Cloughesy T. F., Nelson S. F., Distinct transcription profiles of primary and secondary glioblastoma subgroups Cancer Research 2006 66 1 159 167
30. Henson J. W., Schnitker B. L., Correa K. M., Von Deimling A., Fassbender F., Xu H.-J., Benedict W. F., Yandell D. W., Louis D. N., The retinoblastoma gene is involved in malignant progression of astrocytomas Annals of Neurology 1994 36 5 714 721
31. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H., Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene Carcinogenesis 2001 22 10 1715 1719
32. Donson A. M., Addo-Yobo S. O., Handler M. H., Gore L., Foreman N. K., MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma Pediatric Blood and Cancer 2007 48 4 403 407
33. Chinot O. L., Barri M., Fuentes S., Eudes N., Lancelot S., Metellus P., Muracciole X., Braguer D., Ouafik L., Martin P.-M., Dufour H., Figarella-Branger D., Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide Journal of Clinical Oncology 2007 25 12 1470 1475
34. Hegi M. E., Diserens A.-C., Gorlia T., Hamou M.-F., De Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E. C., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R., MGMT gene silencing and benefit from temozolomide in glioblastoma The New England Journal of Medicine 2005 352 10 997 1003
35. Rood B. R., MacDonald T. J., Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches Journal of Neuro-Oncology 2005 75 3 267 272
36. Sung T., Miller D. C., Hayes R. L., Alonso M., Yee H., Newcomb E. W., Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas Brain Pathology 2000 10 2 249 259
37. Pollack I. F., Finkelstein S. D., Woods J., Burnham J., Holmes E. J., Hamilton R. L., Yates A. J., Boyett J. M., Finlay J. L., posto R., Expression of p53 and prognosis in children with malignant gliomas The New England Journal of Medicine 2002 346 6 420 427
38. Beadle C., Assanah M. C., Monzo P., Vallee R., Rosenfeld S. S., Canoll P., The role of myosin II in glioma invasion of the brain Molecular Biology of the Cell 2008 19 8 3357 3368
39. Caspani E. M., Echevarria D., Rottner K., Small J. V., Live imaging of glioblastoma cells in brain tissue shows requirement of actin bundles for migration Neuron Glia Biology 2006 2 2 105 114
40. Friedl P., Wolf K., Tumour-cell invasion and migration: diversity and escape mechanisms Nature Reviews Cancer 2003 3 5 362 374
41. Friedl P., Prespecification and plasticity: shifting mechanisms of cell migration Current Opinion in Cell Biology 2004 16 1 14 23
42. Li H., Fan X., Houghton J., Tumor microenvironment: the role of the tumor stroma in cancer Journal of Cellular Biochemistry 2007 101 4 805 815
43. Giese A., Kluwe L., Laube B., Meissner H., Berens M. E., Westphal M., Migration of human glioma cells on myelin Neurosurgery 1996 38 4 755 764
44. Demuth T., Berens M. E., Molecular mechanisms of glioma cell migration and invasion Journal of Neuro-Oncology 2004 70 2 217 228
45. Lauffenburger D. A., Horwitz A. F., Cell migration: a physically integrated molecular process Cell 1996 84 3 359 369
46. Laukaitis C. M., Webb D. J., Donais K., Horwitz A. F., Differential dynamics of 5 integrin, paxillin, and -actinin during formation and disassembly of adhesions in migrating cells The Journal of Cell Biology 2001 153 7 1427 1440
47. Burridge K., Chrzanowska-Wodnicka M., Focal adhesions, contractility, and signaling Annual Review of Cell and Developmental Biology 1996 12 463 519
48. Marlin S. D., Springer T. A., Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) Cell 1987 51 5 813 819
49. Heino J., Kpyl J., Cellular receptors of extracellular matrix molecules Current Pharmaceutical Design 2009 15 12 1309 1317
50. Heino J., Huhtala M., Kpyl J., Johnson M. S., Evolution of collagen-based adhesion systems International Journal of Biochemistry Cell Biology 2009 41 2 341 348
51. Hood J. D., Cheresh D. A., Role of integrins in cell invasion and migration Nature Reviews Cancer 2002 2 2 91 100
52. Felding-Habermann B., Integrin adhesion receptors in tumor metastasis Clinical Experimental Metastasis 2003 20 3 203 213
53. Putz E., Witter K., Offner S., Stosiek P., Zippelius A., Johnson J., Zahn R., Riethmller G., Pantel K., Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases Cancer Research 1999 59 1 241 248
54. Cooper C. R., Pienta K. J., Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview Prostate Cancer and Prostatic Diseases 2000 3 1 6 12
55. Hynes R. O., A reevaluation of integrins as regulators of angiogenesis Nature Medicine 2002 8 9 918 921
56. Meyer A., Auernheimer J., Modlinger A., Kessler H., Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting Current Pharmaceutical Design 2006 12 22 2723 2747
57. Pierschbacher M. D., Ruoslahti E., Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule Nature 1984 309 5963 30 33
58. Schottelius M., Laufer B., Kessler H., Wester H.-J., Ligands for mapping v3 -integrin expression in vivo Accounts of Chemical Research 2009 42 7 969 980
59. Gladson C. L., Expression of integrin v3 in small blood vessels of glioblastoma tumors Journal of Neuropathology and Experimental Neurology 1996 55 11 1143 1149
60. Zaidel-Bar R., Ballestrem C., Kam Z., Geiger B., Early molecular events in the assembly of matrix adhesions at the leading edge of migrating cells Journal of Cell Science 2003 116 22 4605 4613
61. White D. P., Caswell P. T., Norman J. C., v 3 and 5 1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration The Journal of Cell Biology 2007 177 3 515 525
62. Abdollahi A., Griggs D. W., Zieher H., Roth A., Lipson K. E., Saffrich R., Grne H.-J., Hallahan D. E., Reisfeld R. A., Debus J., Niethammer A. G., Huber P. E., Inhibition of v3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy Clinical Cancer Research 2005 11 17 6270 6279
63. Hsu A. R., Veeravagu A., Cai W., Hou L. C., Tse V., Chen X., Integrin v 3 antagonists for anti-angiogenic cancer treatment Recent Patents on Anti-Cancer Drug Discovery 2007 2 2 143 158
64. Lim M., Guccione S., Haddix T., Sims L., Cheshier S., Chu P., Vogel H., Harsh G., v 3 Integrin in central nervous system tumors Human Pathology 2005 36 6 665 669
65. Mahabeleshwar G. H., Feng W., Reddy K., Plow E. F., Byzova T. V., Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis Circulation Research 2007 101 6 570 580
66. Riemenschneider M. J., Mueller W., Betensky R. A., Mohapatra G., Louis D. N., In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation American Journal of Pathology 2005 167 5 1379 1387
67. Veeravagu A., Liu Z., Niu G., Integrin v3 -targeted radioimmunotherapy of glioblastoma multiforme Clinical Cancer Research 2008 14 22 7330 7339
68. Zagzag D., Friedlander D. R., Margolis B., Grumet M., Semenza G. L., Zhong H., Simons J. W., Holash J., Wiegand S. J., Yancopoulos G. D., Molecular events implicated in brain tumor angiogenesis and invasion Pediatric Neurosurgery 2000 33 1 49 55
69. Natarajan M., Hecker T. P., Gladson C. L., FAK signaling in anaplastic astrocytoma and glioblastoma tumors Cancer Journal 2003 9 2 126 133
70. Natarajan M., Stewart J. E. Jr., Golemis E. A., Pugacheva E. N., Alexandropoulos K., Cox B. D., Wang W., Grammer J. R., Gladson C. L., HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells Oncogene 2006 25 12 1721 1732
71. de Groot J., Milano V., Improving the prognosis for patients with glioblastoma: the rationale for targeting Src Journal of Neuro-Oncology 2009 95 2 151 163
72. Zaidel-Bar R., Itzkovitz S., Ma'ayan A., Iyengar R., Geiger B., Functional atlas of the integrin adhesome Nature Cell Biology 2007 9 8 858 867
73. Sieg D. J., Hauck C. R., Schlaepfer D. D., Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration Journal of Cell Science 1999 112 16 2677 2691
74. Webb D. J., Donais K., Whitmore L. A., Thomas S. M., Turner C. E., Parsons J. T., Horwitz A. F., FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly Nature Cell Biology 2004 6 2 154 161
75. Ilic D., Furuta Y., Kanazawa S., Takeda N., Sobue K., Nakatsuji N., Nomura S., Fujimoto J., Okada M., Yamasnoto T., Aizawa S., Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice Nature 1995 377 6549 539 544
76. Cary L. A., Chang J. F., Guan J.-L., Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn Journal of Cell Science 1996 109 7 1787 1794
77. Cary L. A., Han D. C., Polte T. R., Hanks S. K., Guan J.-L., Identification of p 130Cas as a mediator of focal adhesion kinase-promoted cell migration The Journal of Cell Biology 1998 140 1 211 221
78. Owens L. V., Xu L., Craven R. J., Dent G. A., Weiner T. M., Kornberg L., Liu E. T., Cance W. G., Overexpression of the focal adhesion kinase (p 125FAK) in invasive human tumors Cancer Research 1995 55 13 2752 2755
79. Lietha D., Cai X., Ceccarelli D. F. J., Li Y., Schaller M. D., Eck M. J., Structural basis for the autoinhibition of focal adhesion kinase Cell 2007 129 6 1177 1187
80. Calalb M. B., Polte T. R., Hanks S. K., Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases Molecular and Cellular Biology 1995 15 2 954 963
81. Schlaepfer D. D., Hunter T., Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases Molecular and Cellular Biology 1996 16 10 5623 5633
82. Schlaepfer D. D., Jones K. C., Hunter T., Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events? Molecular and Cellular Biology 1998 18 5 2571 2585
83. Chen H.-C., Appeddu P. A., Isoda H., Guan J.-L., Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase Journal of Biological Chemistry 1996 271 42 26329 26334
84. Hildebrand J. D., Taylor J. M., Parsons J. T., An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase Molecular and Cellular Biology 1996 16 6 3169 3178
85. Richardson A., Malik R. K., Hildebrand J. D., Parsons J. T., Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation Molecular and Cellular Biology 1997 17 12 6906 6914
86. O'Neill G. M., Fashena S. J., Golemis E. A., Integrin signalling: a new Cas(t) of characters enters the stage Trends in Cell Biology 2000 10 3 111 119
87. Ruest P. J., Shin N.-Y., Polte T. R., Zhang X., Hanks S. K., Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src Molecular and Cellular Biology 2001 21 22 7641 7652
88. Singh M. K., Cowell L., Seo S., O'Neill G. M., Golemis E. A., Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle Cell Biochemistry and Biophysics 2007 48 1 54 72
89. Gutenberg A., Brck W., Buchfelder M., Ludwig H. C., Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas Acta Neuropathologica 2004 108 3 224 230
90. Zrihan-Licht S., Fu Y., Settleman J., Schinkmann K., Shaw L., Keydar I., Avraham S., Avraham H., RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion Oncogene 2000 19 10 1318 1328
91. Lipinski C. A., Tran N. L., Viso C., Kloss J., Yang Z., Berens M. E., Loftus J. C., Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts Journal of Neuro-Oncology 2008 90 2 181 189
92. Brunton V. G., Frame M. C., Src and focal adhesion kinase as therapeutic targets in cancer Current Opinion in Pharmacology 2008 8 4 427 432
93. Fincham V. J., Frame M. C., The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility The EMBO Journal 1998 17 1 81 92
94. Zaidel-Bar R., Milo R., Kam Z., Geiger B., A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions Journal of Cell Science 2007 120 1 137 148
95. Bach C. T. T., Creed S., Zhong J., Mahmassani M., Schevzov G., Stehn J., Cowell L. N., Naumanen P., Lappalainen P., Gunning P. W., O'Neill G. M., Tropomyosin isoform expression regulates the transition of adhesions to determine cell speed and direction Molecular and Cellular Biology 2009 29 6 1506 1514
96. Goldberg G. S., Alexander D. B., Pellicena P., Zhang Z.-Y., Tsuda H., Miller W. T., Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells Journal of Biological Chemistry 2003 278 47 46533 46540
97. Shin N.-Y., Dise R. S., Schneider-Mergener J., Ritchie M. D., Kilkenny D. M., Hanks S. K., Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration Journal of Biological Chemistry 2004 279 37 38331 38337
98. Brbek J., Constancio S. S., Siesser P. F., Shin N.-Y., Pozzi A., Hanks S. K., Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of Src-transformed cells Molecular Cancer Research 2005 3 6 307 315
99. Playford M. P., Schaller M. D., The interplay between Src and integrins in normal and tumor biology Oncogene 2004 23 48 7928 7946
100. Klemke R. L., Leng J., Molander R., Brooks P. C., Vuori K., Cheresh D. A., CAS/Crk coupling serves as a molecular switch for induction of cell migration The Journal of Cell Biology 1998 140 4 961 972
101. Cheresh D. A., Leng J., Klemke R. L., Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells The Journal of Cell Biology 1999 146 5 1107 1116
102. Sanz-Moreno V., Marshall C. J., Rho-GTPase signaling drives melanoma cell plasticity Cell Cycle 2009 8 10 1484 1487
103. Bellis S. L., Miller J. T., Turner C. E., Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase Journal of Biological Chemistry 1995 270 29 17437 17441
104. Schaller M. D., Parsons J. T., pp 125FAK -dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk Molecular and Cellular Biology 1995 15 5 2635 2645
105. Schlaepfer D. D., Hanks S. K., Hunter T., van der Geer P., Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase Nature 1994 372 6508 786 791
106. Cramer L. P., Organization and polarity of actin filament networks in cells: implications for the mechanism of myosin-based cell motility Biochemical Society Symposium 1999 65 173 205
107. Humphries J. D., Wang P., Streuli C., Geiger B., Humphries M. J., Ballestrem C., Vinculin controls focal adhesion formation by direct interactions with talin and actin The Journal of Cell Biology 2007 179 5 1043 1057
108. Katoh K., Kano Y., Amano M., Onishi H., Kaibuchi K., Fujiwara K., Rho-kinasemediated contraction of isolated stress fibers The Journal of Cell Biology 2001 153 3 569 584
109. Verkhovsky A. B., Svitkina T. M., Borisy G. G., Myosin II filament assemblies in the active lamella of fibroblasts: their morphogenesis and role in the formation of actin filament bundles The Journal of Cell Biology 1995 131 4 989 1002
110. Kamm K. E., Stull J. T., Dedicated myosin light chain kinases with diverse cellular functions Journal of Biological Chemistry 2001 276 7 4527 4530
111. Fukata Y., Kaibuchi K., Amano M., Kaibuchi K., Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells Trends in Pharmacological Sciences 2001 22 1 32 39
112. Albiges-Rizo C., Destaing O., Fourcade B., Planus E., Block M. R., Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions Journal of Cell Science 2009 122 17 3037 3049
113. Ridley A. J., Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking Trends in Cell Biology 2006 16 10 522 529
114. Sukumvanich P., DesMarais V., Sarmiento C. V., Wang Y., Ichetovkin I., Mouneimne G., Almo S., Condeelis J., Cellular localization of activated N-WASP using a conformation-sensitive antibody Cell Motility and the Cytoskeleton 2004 59 2 141 152
115. Nobes C. D., Hall A., Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia Cell 1995 81 1 53 62
116. Rohatgi R., Ma L., Miki H., Lopez M., Kirchhausen T., Takenawa T., Kirschner M. W., The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly Cell 1999 97 2 221 231
117. Butler B., Gao C., Mersich A. T., Blystone S. D., Purified integrin adhesion complexes exhibit actin-polymerization activity Current Biology 2006 16 3 242 251
118. DeMali K. A., Barlow C. A., Burridge K., Recruitment of the Arp2/3 complex to vinculin: coupling membrane protrusion to matrix adhesion The Journal of Cell Biology 2002 159 5 881 891
119. Coll J.-L., Ben-Ze'ev A., Ezzell R. M., Rodrguez Fernndez J. L., Baribault H., Oshima R. G., Adamson E. D., Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion Proceedings of the National Academy of Sciences of the United States of America 1995 92 20 9161 9165
120. Xu W., Coll J.-L., Adamson E. D., Rescue of the mutant phenotype by reexpression of full-length vinculin in null F9 cells; effects on cell locomotion by domain deleted vinculin Journal of Cell Science 1998 111 11 1535 1544
121. Serrels B., Serrels A., Brunton V. G., Holt M., McLean G. W., Gray C. H., Jones G. E., Frame M. C., Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex Nature Cell Biology 2007 9 9 1046 1056
122. Nobes C. D., Hall A., Rho GTPases control polarity, protrusion, and adhesion during cell movement The Journal of Cell Biology 1999 144 6 1235 1244
123. Aspenstrm P., Fransson., Saras J., Rho GTPases have diverse effects on the organization of the actin filament system The Biochemical Journal 2004 377 2 327 337
124. Ellis S., Mellor H., The novel Rho-family GTPase Rif regulates coordinated actin-based membrane rearrangements Current Biology 2000 10 21 1387 1390
125. Murphy G. A., Solski P. A., Jillian S. A., Prez de la Ossa P., D'Eustachio P., Der C. J., Rush M. G., Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth Oncogene 1999 18 26 3831 3845
126. Ridley A. J., Schwartz M. A., Burridge K., Firtel R. A., Ginsberg M. H., Borisy G., Parsons J. T., Horwitz A. R., Cell Migration: integrating signals from front to back Science 2003 302 5651 1704 1709
127. Ridley A. J., Hall A., The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors Cell 1992 70 3 389 399
128. Rottner K., Hall A., Small J. V., Interplay between Rac and Rho in the control of substrate contact dynamics Current Biology 1999 9 12 640 648
129. Kraynov V. S., Chamberlain C., Bokoch G. M., Schwartz M. A., Slabaugh S., Hahn K. M., Localized Rac activation dynamics visualized in living cells Science 2000 290 5490 333 337
130. Ridley A. J., Rho GTPases and cell migration Journal of Cell Science 2001 114 15 2713 2722
131. Cho S. Y., Klemke R. L., Purification of pseudopodia from polarized cells reveals redistribution and activation of Rac through assembly of a CAS/Crk scaffold The Journal of Cell Biology 2002 156 4 725 736
132. Yeo M. G., Song W. K., v-Crk regulates membrane dynamics and Rac activation Cell Adhesion amp; Migration 2008 2 3 174 176
133. Keely P. J., Westwick J. K., Whitehead I. P., Der C. J., Parise L. V., Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K Nature 1997 390 6660 632 636
134. Yamazaki D., Kurisu S., Takenawa T., Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates Oncogene 2009 28 13 1570 1583
135. Desmarais V., Ghosh M., Eddy R., Condeelis J., Cofilin takes the lead Journal of Cell Science 2005 118 1 19 26
136. Huang T. Y., Dermardirossian C., Bokoch G. M., Cofilin phosphatases and regulation of actin dynamics Current Opinion in Cell Biology 2006 18 1 26 31
137. Mouneimne G., Soon L., DesMarais V., Sidani M., Song X., Yip S.-C., Ghosh M., Eddy R., Backer J. M., Condeelis J., Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation The Journal of Cell Biology 2004 166 5 697 708
138. Kaye A. H., Laws E. R., Historical perspective Brain Tumors 1995 New York, NY, USA Churchill Livingstone 3 8
139. Hillier W. F. Jr., Total left cerebral hemispherectomy for malignant glioma Neurology 1954 4 9 718 721
140. Bouchard J., Pierce C. B., Radiation therapy in the management of neoplasms of the central nervous system, with a special note in regard to children: twenty years experience American Journal of Roentgenology 1960 84 610 628
141. Wen P. Y., Kesari S., Malignant gliomas in adults The New England Journal of Medicine 2008 359 5 492 507
142. Simpson J. R., Horton J., Curran W. J., Rubin P., Fischbach J., Isaacson S., Rotman M., Asbell S. O., Nelson J. S., Weinstein A. S., Nelson D. F., Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials International Journal of Radiation Oncology Biology Physics 1993 26 2 239 244
143. Fazeny-Dorner B., Wenzel C., Veitl M., Piribauer M., Rssler K., Dieckmann K., Ungersbck K., Marosi C., Survival and prognostic factors of patients with unresectable glioblastoma multiforme Anti-Cancer Drugs 2003 14 4 305 312
144. Cohen M. H., Johnson J. R., Pazdur R., Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme Clinical Cancer Research 2005 11 19, part 1 6767 6771
145. Macdonald D. R., Kiebert G., Prados M., Yung A., Olson J., Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life Cancer Investigation 2005 23 2 138 144
146. Yung W. K. A., Albright R. E., Olson J., Fredericks R., Fink K., Prados M. D., Brada M., Spence A., Hohl R. J., Shapiro W., Glantz M., Greenberg H., Selker R. G., Vick N. A., Rampling R., Friedman H., Phillips P., Bruner J., Yue N., Osoba D., Zaknoen S., Levin V. A., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse British Journal of Cancer 2000 83 5 588 593 (Pubitemid 30636298)
147. Hart M. G., Grant R., Garside R., Rogers G., Somerville M., Stein K., Temozolomide for high grade glioma Cochrane Database of Systematic Reviews 2008 4, article no. CD007415
148. Fischer I., Gagner J.-P., Law M., Newcomb E. W., Zagzag D., Angiogenesis in gliomas: biology and molecular pathophysiology Brain Pathology 2005 15 4 297 310
149. Kunkel P., Ulbricht U., Bohlen P., Brockmann M. A., Fillbrandt R., Stavrou D., Westphal M., Lamszus K., Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Research 2001 61 18 6624 6628
150. Winkler F., Kienast Y., Fuhrmann M., Von Baumgarten L., Burgold S., Mitteregger G., Kretzschmar H., Herms J., Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis Glia 2009 57 12 1306 1315
151. Rubenstein J. L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D. F., Shuman M. A., Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2000 2 4 306 314
152. Norden A. D., Young G. S., Setayesh K., Muzikansky A., Klufas R., Ross G. L., Ciampa A. S., Ebbeling L. G., Levy B., Drappatz J., Kesari S., Wen P. Y., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 2008 70 10 779 787
153. Drappatz J., Norden A. D., Wen P. Y., Therapeutic strategies for inhibiting invasion in glioblastoma Expert Review of Neurotherapeutics 2009 9 4 519 534
154. Maurer G. D., Tritschler I., Adams B., Tabatabai G., Wick W., Stupp R., Weller M., Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro Neuro-Oncology 2009 11 6 747 756
155. Gladson C. L., Cheresh D. A., Glioblastoma expression of vitronectin and the v3 integrin. Adhesion mechanism for transformed glial cells Journal of Clinical Investigation 1991 88 6 1924 1932
156. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R. S., Nikas D. C., Strasser J. F., Villani R., Cheresh D. A., McL. Black P., v 3 and v5 integrin expression in glioma periphery Neurosurgery 2001 49 2 380 390
157. Frisch S. M., Vuori K., Ruoslahti E., Chan-Hui P.-Y., Control of adhesion-dependent cell survival by focal adhesion kinase The Journal of Cell Biology 1996 134 3 793 799
158. Alghisi G., Regg C., Vascular integrins in tumor angiogenesis: mediators and therapeutic targets Endothelium 2006 13 2 113 135
159. Felding-Habermann B., O'Toole T. E., Smith J. W., Fransvea E., Ruggeri Z. M., Ginsberg M. H., Hughes P. E., Pampori N., Shattil S. J., Saven A., Mueller B. M., Integrin activation controls metastasis in human breast cancer
160. Gasparini G., Brooks P. C., Biganzoli E., Vermeulen P. B., Bonoldi E., Dirix L. Y., Ranieri G., Miceli R., Cheresh D. A., Vascular integrin v3: a new prognostic indicator in breast cancer Clinical Cancer Research 1998 4 11 2625 2634
161. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
162. Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A., Definition of two angiogenic pathways by distinct alpha v integrins Science 1995 270 5241 1500 1502
163. Dechantsreiter M. A., Planker E., Math B., Lohof E., Hlzemann G., Jonczyk A., Goodman S. L., Kessler H., N -methylated cyclic RGD peptides as highly active and selective v3 integrin antagonists Journal of Medicinal Chemistry 1999 42 16 3033 3040
164. Reardon D. A., Nabors L. B., Stupp R., Mikkelsen T., Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme Expert Opinion on Investigational Drugs 2008 17 8 1225 1235
165. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., Schuch G., Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/Src/AKT pathway Journal of Experimental and Clinical Cancer Research 2008 27 1 86
166. Yamada S., Bu X.-Y., Khankaldyyan V., Gonzales-Gomez I., McComb J. G., Laug W. E., Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice Neurosurgery 2006 59 6 1304 1312
167. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra F., Casara P. J., Hickman J. A., Tucker G. C., Van Obberghen-Schilling E., Blockade of v 3 and v 5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells Blood 2006 108 9 3035 3044
168. Taga T., Suzuki A., Gonzalez-Gomez I., Gilles F. H., Stins M., Shimada H., Barsky L., Weinberg K. I., Laug W. E., v -integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin International Journal of Cancer 2002 98 5 690 697
169. Reardon D. A., Fink K. L., Mikkelsen T., Cloughesy T. F., O'Neill A., Plotkin S., Glantz M., Ravin P., Raizer J. J., Rich K. M., Schiff D., Shapiro W. R., Burdette-Radoux S., Dropcho E. J., Wittemer S. M., Nippgen J., Picard M., Nabors L. B., Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme Journal of Clinical Oncology 2008 26 34 5610 5617
170. Nabors L. B., Mikkelsen T., Rosenfeld S. S., Hochberg F., Akella N. S., Fisher J. D., Cloud G. A., Zhang Y., Carson K., Wittemer S. M., Colevas A. D., Grossman S. A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma Journal of Clinical Oncology 2007 25 13 1651 1657
171. Stupp R., Ruegg C., Integrin inhibitors reaching the clinic Journal of Clinical Oncology 2007 25 13 1637 1638
172. Hariharan S., Gustafson D., Holden S., McConkey D., Davis D., Morrow M., Basche M., Gore L., Zang C., O'Bryant C. L., Baron A., Gallemann D., Colevas D., Eckhardt S. G., Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors Annals of Oncology 2007 18 8 1400 1407
173. Burke P. A., DeNardo S. J., Miers L. A., Lamborn K. R., Matzku S., DeNardo G. L., Cilengitide targeting of v3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts Cancer Research 2002 62 15 4263 4272
174. Shi Q., Hjelmeland A. B., Keir S. T., Song L., Wickman S., Jackson D., Ohmori O., Bigner D. D., Friedman H. S., Rich J. N., A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth Molecular Carcinogenesis 2007 46 6 488 496
175. Schultze A., Decker S., Otten J., Horst A. K., Vohwinkel G., Schuch G., Bokemeyer C., Loges S., Fiedler W., TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis Investigational New Drugs 2009 1 9
176. Beierle E. A., Trujillo A., Nagaram A., Golubovskaya V. M., Cance W. G., Kurenova E. V., TAE226 inhibits human neuroblastoma cell survival Cancer Investigation 2008 26 2 145 151
177. Halder J., Lin Y. G., Merritt W. M., Spannuth W. A., Nick A. M., Honda T., Kamat A. A., Han L. Y., Tae J. K., Lu C., Tari A. M., Bornmann W., Fernandez A., Lopez-Berestein G., Sood A. K., Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma Cancer Research 2007 67 22 10976 10983
178. Angers-Loustau A., Hering R., Werbowetski T. E., Kaplan D. R., Del Maestro R. F., Src regulates actin dynamics and invasion of malignant glial cells in three dimensions Molecular Cancer Research 2004 2 11 595 605
179. Lu K. V., Zhu S., Cvrljevic A., Huang T. T., Sarkaria S., Ahkavan D., Dang J., Dinca E. B., Plaisier S. B., Oderberg I., Lee Y., Chen Z., Caldwell J. S., Xie Y., Loo J. A., Seligson D., Chakravari A., Lee F. Y., Weinmann R., Cloughesy T. F., Nelson S. F., Bergers G., Graeber T., Furnari F. B., David James C., Cavenee W. K., Johns T. G., Mischel P. S., Fyn and Src are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients Cancer Research 2009 69 17 6889 6898
180. Milano V., Piao Y., Lafortune T., De Groot J., Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma Molecular Cancer Therapeutics 2009 8 2 394 406
181. Cuneo K. C., Geng L., Tan J., Brousal J., Shinohara E. T., Osusky K., Fu A., Shyr Y., Wu H., Hallahan D. E., Src family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation International Journal of Radiation Oncology Biology Physics 2006 64 4 1197 1203
182. Green T. P., Fennell M., Whittaker R., Curwen J., Jacobs V., Allen J., Logie A., Hargreaves J., Hickinson D. M., Wilkinson R. W., Elvin P., Boyer B., Carragher N., Pl P. A., Bermingham A., Holdgate G. A., Ward W. H. J., Hennequin L. F., Davies B. R., Costello G. F., Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 Molecular Oncology 2009 3 3 248 261
183. Purnell P. R., Mack P. C., Tepper C. G., Evans C. P., Green T. P., Gumerlock P. H., Lara P. N., Gandara D. R., Kung H.-J., Gautschi O., The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells Journal of Thoracic Oncology 2009 4 4 448 454
184. Guertin D. A., Sabatini D. M., An expanding role for mTOR in cancer Trends in Molecular Medicine 2005 11 8 353 361
185. Liu L., Chen L., Chung J., Huang S., Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins Oncogene 2008 27 37 4998 5010
186. Neshat M. S., Mellinghoff I. K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J. J., Wu H., Sawyers C. L., Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proceedings of the National Academy of Sciences of the United States of America 2001 98 18 10314 10319
187. Cloughesy T. F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P. S., Mellinghoff I. K., Sawyers C. L., Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Medicine 2008 5 1, article e8
188. Galanis E., Buckner J. C., Maurer M. J., Kreisberg J. I., Ballman K., Boni J., Peralba J. M., Jenkins R. B., Dakhil S. R., Morton R. F., Jaeckle K. A., Scheithauer B. W., Dancey J., Hidalgo M., Walsh D. J., Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study Journal of Clinical Oncology 2005 23 23 5294 5304 (Pubitemid 46206983)
189. Paulus W., Baur I., Beutler A. S., Reeves S. A., Diffuse brain invasion of glioma cells requires beta 1 integrins Laboratory Investigation 1996 75 6 819 826
190. Cruet-Hennequart S., Maubant S., Luis J., Gauduchon P., Staedel C., Dedhar S., v integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells Oncogene 2003 22 11 1688 1702
191. Lorger M., Krueger J. S., O'Neal M., Staflin K., Felding-Habermann B., Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain Proceedings of the National Academy of Sciences of the United States of America 2009 106 26 10666 10671
192. Paulus W., Baur I., Huettner C., Schmausser B., Roggendorf W., Schlingensiepen K. H., Brysch W., Effects of transforming growth factor- 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells Journal of Neuropathology and Experimental Neurology 1995 54 2 236 244
193. Friedl P., Znker K. S., Brcker E.-B., Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function Microscopy Research and Technique 1998 43 5 369 378
194. Mueller S. C., Ghersi G., Akiyama S. K., Sang Q.-X. A., Howard L., Pineiro-Sanchez M., Nakahara H., Yeh Y., Chen W.-T., A novel protease-docking function of integrin at invadopodia Journal of Biological Chemistry 1999 274 35 24947 24952
195. Ohuchi E., Imai K., Fuj Y. II, Sato H., Seiki M., Okada Y., Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules Journal of Biological Chemistry 1997 272 4 2446 2451
196. Friedl P., Wolf K., Proteolytic and non-proteolytic migration of tumour cells and leucocytes Biochemical Society Symposium 2003 70 277 285
197. Stukel J. M., Li R. C., Maynard H. D., Caplan M. R., Two-step synthesis of multivalent cancer-targeting constructs Biomacromolecules 2010 11 1 160 167
198. Drappatz J., Norden A. D., Wen P. Y., Therapeutic strategies for inhibiting invasion in glioblastoma Expert Review of Neurotherapeutics 2009 9 4 519 534
199. Bryce N. S., Schevzov G., Ferguson V., Percival J. M., Lin J.J.-C., Matsumura F., Bamburg J. R., Jeffrey P. L., Hardeman E. C., Gunning P., Weinberger R. P., Specification of actin filament function and molecular composition by tropomyosin isoforms Molecular Biology of the Cell 2003 14 3 1002 1016
200. Gupton S. L., Anderson K. L., Kole T. P., Fischer R. S., Ponti A., Hitchcock-DeGregori S. E., Danuser G., Fowler V. M., Wirtz D., Hanein D., Waterman-Storer C. M., Cell migration without a lamellipodium: translation of actin dynamics into cell movement mediated by tropomyosin The Journal of Cell Biology 2005 168 4 619 631
201. O'Neill G. M., The coordination between actin filaments and adhesion in mesenchymal migration Cell Adhesion and Migration 2009 3 4 355 357
202. O'Neill G. M., Stehn J., Gunning P. W., Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton Seminars in Cancer Biology 2008 18 1 35 44
203. Stehn J. R., Schevzov G., O'Neill G. M., Gunning P. W., Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy Current Cancer Drug Targets 2006 6 3 245 256
204. Wang W., Eddy R., Condeelis J., The cofilin pathway in breast cancer invasion and metastasis Nature Reviews Cancer 2007 7 6 429 440
205. Gunnersen J. M., Spirkoska V., Smith P. E., Andrew Danks R., Tan S.-S., Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression Glia 2000 32 2 146 154
206. Yap C. T., Simpson T. I., Pratt T., Price D. J., Maciver S. K., The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner Cell Motility and the Cytoskeleton 2005 60 3 153 165
207. Wang W., Mouneimne G., Sidani M., Wyckoff J., Chen X., Makris A., Goswami S., Bresnick A. R., Condeelis J. S., The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors Journal of Cell Biology 2006 173 3 395 404
208. Lee Y.-J., Mazzatti D. J., Yun Z., Keng P. C., Inhibition of invasiveness of human lung cancer cell line H1299 by over-expression of cofilin Cell Biology International 2005 29 11 877 883
209. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C. J., Rac activation and inactivation control plasticity of tumor cell movement Cell 2008 135 3 510 523
210. Ridley A. J., Allen W. E., Peppelenbosch M., Jones G. E., Rho family proteins and cell migration Biochemical Society Symposium 1999 65 111 123
211. Senger D. L., Tudan C., Guiot M.-C., Mazzoni I. E., Molenkamp G., LeBlanc R., Antel J., Olivier A., Snipes G. J., Kaplan D. R., Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes Cancer Research 2002 62 7 2131 2140
212. Joy A. M., Beaudry C. E., Tran N. L., Ponce F. A., Holz D. R., Demuth T., Berens M. E., Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis Journal of Cell Science 2003 116 21 4409 4417
213. Mehlen P., Puisieux A., Metastasis: a question of life or death Nature Reviews Cancer 2006 6 6 449 458
214. Boyer B., Tucker G. C., Valles A. M., Gavrilovic J., Thiery J. P., Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line International Journal of Cancer 1989 4 69 75
215. Thiery J. P., Epithelial-mesenchymal transitions in tumour progression Nature reviews Cancer 2002 2 6 442 454
216. Gao Y., Dickerson J. B., Guo F., Zheng J., Zheng Y., Rational design and characterization of a Rac GTPase-specific small molecule inhibitor Proceedings of the National Academy of Sciences of the United States of America 2004 101 20 7618 7623
217. Vivanco I., Sawyers C. L., The phosphatidylinositol 3-kinase-AKT pathway in human cancer Nature Reviews Cancer 2002 2 7 489 501
218. Kodaki T., Woscholski R., Hallberg B., Rodriguez-Viciana P., Downward J., Parker P. J., The activation of phosphatidylinositol 3-kinase by Ras Current Biology 1994 4 9 798 806
219. Rodriguez-Viciana P., Warne P. H., Dhand R., Vanhaesebroeck B., Gout I., Fry M. J., Waterfield M. D., Downward J., Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature 1994 370 6490 527 532
220. Stokoe D., Stephens L. R., Copeland T., Gaffney P. R. J., Reese C. B., Painter G. F., Holmes A. B., McCormick F., Hawkins P. T., Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B Science 1997 277 5325 567 570
221. Vanhaesebroeck B., Alessi D. R., The PI3K-PBK1 connection: more than just a road to PKB Biochemical Journal 2000 346 3 561 576
222. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wigler M. H., Parsons R., PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 1997 275 5308 1943 1947
223. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K. A., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. H. F., Tavtigian S. V., Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nature Genetics 1997 15 4 356 362
224. Kotelevets L., van Hengel J., Bruyneel E., Mareel M., Van Roy F., Chastre E., The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness The Journal of Cell Biology 2001 155 7 1129 1135
225. Liliental J., Moon S. Y., Lesche R., Mamillapalli R., Li D., Zheng Y., Sun H., Wu H., Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases Current Biology 2000 10 7 401 404
226. Howes A. L., Chiang G. G., Lang E. S., Ho C. B., Powis G., Vuori K., Abraham R. T., The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures Molecular Cancer Therapeutics 2007 6 9 2505 2514
227. Simpson K. J., Selfors L. M., Bui J., Reynolds A., Leake D., Khvorova A., Brugge J. S., Identification of genes that regulate epithelial cell migration using an siRNA screening approach Nature Cell Biology 2008 10 9 1027 1038
228. McDonald K. L., O'Sullivan M. G., Parkinson J. F., Shaw J. M., Payne C. A., Brewer J. M., Young L., Reader D. J., Wheeler H. T., Cook R. J., Biggs M. T., Little N. S., Teo C., Stone G., Robinson B. G., IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients Journal of Neuropathology and Experimental Neurology 2007 66 5 405 417
229. Parkinson J. F., Wheeler H. R., Clarkson A., McKenzie C. A., Biggs M. T., Little N. S., Cook R. J., Messina M., Robinson B. G., McDonald K. L., Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma Journal of Neuro-Oncology 2008 87 1 71 78
230. Payne C. A., Maleki S., Messina M., O'Sullivan M. G., Stone G., Hall N. R., Parkinson J. F., Wheeler H. R., Cook R. J., Biggs M. T., Little N. S., Teo C., Robinson B. G., McDonald K. L., Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma Molecular Cancer Therapeutics 2008 7 10 3420 3428
231. Moreau D., Jacquot C., Tsita P., Chinou I., Tomasoni C., Juge M., Antoniadou-Vyza E., Martignat L., Pineau A., Roussakis C., Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer International Journal of Cancer 2008 123 11 2676 2683
232. de Boer A. G., Gaillard P. J., Drug targeting to the brain Annual Review of Pharmacology and Toxicology 2007 47 323 355
233. Miller D. S., Bauer B., Hartz A. M. S., Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacological Reviews 2008 60 2 196 209
234. Stukel J. M., Caplan M. R., Targeted drug delivery for treatment and imaging of glioblastoma multiforme Expert Opinion on Drug Delivery 2009 6 7 705 718
235. Baker S. D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S. E., Dugan M., Cutler D., Batra V., Grochow L. B., Donehower R. C., Rowinsky E. K., Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer Clinical Cancer Research 1999 5 2 309 317
236. Juillerat-Jeanneret L., The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discovery Today 2008 13 23-24 1099 1106
237. Bidros D. S., Vogelbaum M. A., Novel drug delivery strategies in neuro-oncology Neurotherapeutics 2009 6 3 539 546
238. Laquintana V., Trapani A., Denora N., Wang F., Gallo J. M., Trapani G., New strategies to deliver anticancer drugs to brain tumors Expert Opinion on Drug Delivery 2009 6 10 1017 1032
239. Silva G. A., Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS BMC Neuroscience 2008 9 supplement 3, article 4